Sussex Research Online

Neuropsychological function is related to irritable bowel syndrome in women with premenstrual syndrome and dysmenorrhea

Article (Accepted Version)

http://sro.sussex.ac.uk

Neuropsychological function is related to irritable bowel syndrome in women with premenstrual syndrome and dysmenorrhea

Malaksima Ayadilord [1,2*], Sara Mahmoudzadeh[1,2*], Zahra Sadat Hoseini[3], Masoumeh Askari[1,4], Hadis Rezapour[1,2], Mansoore Saharkhiz[1,2], Arefeh Abbaszadeh[1], Samira Karbasi[1,5], Nasrin Zandi Dashtebayaze[5], Gordon A. Ferns[6], Afsane Bahrami[5†]

[1]Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran

[2]Department of Immunology, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran

[3]Department of psychology, University of Birjand, Birjand, Iran

[4]Department of Anatomical Sciences, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran

[5]Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran

[6]Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK

[*] Equally contributed as first author.

†**Corresponding authors:** Dr. Afsane Bahrami, Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran, 9717853577, Tel: +985332381569, Fax: +9856324380076,

Email: Bahramia@bums.ac.ir & Afsbahramia931@gmail.com.

Running title: PMS and IBS

Abstract

Background: There is increasing evidence demonstrating the co-occurrence of primary dysmenorrhea (PD), premenstrual syndrome (PMS), and irritable bowel syndrome (IBS) in women. This study aimed to investigate whether women who have symptoms of IBS in addition to PD and PMS also report more severe or frequent menstruation-associated symptoms and psychological complications compared to women with PD and PMS alone.

Methods: The study group included 182 female University students aged 18-25 years. IBS was diagnosed using the Rome III criteria. The severity of PMS and PD was determined using a 10-point visual analog scale and PSST (Premenstrual Syndrome Screening Tool), respectively. Neuropsychological function including cognitive function, depression score, anxiety score, stress, insomnia, daytime sleepiness, quality of life and personality were assessed using standard questionnaires.

Results: Of the 182 young females, 31(17.0%) had IBS. Average days of bleeding during the menstrual cycle and mean pain severity on the PSST scale were significantly greater in the group with IBS compared to the non-IBS group (P<0.01). The non-IBS individuals scored more favorably than the women with IBS with respect to severity of depression, insomnia, daytime sleepiness (P<0.05). The PSST scores were significantly correlated with scores for depression (r=0.29; p<0.001), anxiety (r=0.28; p<0.001), stress (r=0.32; p<0.001), insomnia (r=0.34; p<0.001) and daytime sleepiness (r=0.31; p<0.001); while they were negatively correlated with cognitive abilities (r=-0.20; p=0.006) and quality of life (r=-0.42; p<0.001). Linear regression analysis showed that the PSST scores were possibly significant factors in determining the scores for depression, anxiety, stress, quality of life, insomnia and daytime sleepiness (P<0.05).

Conclusion: IBS is related to psychological comorbidities, in particular depression, sleep problems and menstrual-associated disorders. IBS may exacerbate the features of PMS which should be taken into account in the management of PMS.

Keywords: Cognitive abilities; Anxiety; Depression; insomnia; quality of life

1. Introduction

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by abdominal pain or discomfort together with alteration of bowel habits in the lack of structural abnormalities [1]. Epidemiologic studies have reported the prevalence of IBS is approaching 11% globally [2] and 1.1% to 25% in Iranian populations [3, 4].

The pathogenesis of IBS involves the interactions of several factors i.e. abnormal gastrointestinal motility, visceral hypersensitivity, and elevated pain perception [5, 6], dietary intolerance [7], disturbance of brain–gut axis function [8, 9], chronic inflammation, changing gut immune induction [10], intestinal permeability and reorganization of microbiota [11], psychosocial stressors and psychiatric comorbidities [12]. Patients with IBS endure high levels of psychological distress; these have been reported to be at intermediate levels between psychiatric cases and healthy individuals[13]. Psychiatric comorbidities such as depression may also be involved in the negative effect of IBS on the quality of life [14]. The large intestine is partly regulated via the autonomic nervous system and reacts to stress. Manifested by increments of the sensation together motility of the large intestine [15].

Sex hormones may also contribute to the etiology of IBS. This is supported by the fact that IBS is more prevalent in women compared to men [16]. Menarche defines the beginning of menstruation and it is one of the most impactful events in a women's life; women of reproductive age are often negatively affected by symptoms corresponding to menstrual dysfunction such as premenstrual syndrome (PMS) and primary dysmenorrhea (PD) [17].

PD can be defined as a presence of spasmodic-like pain in the lower abdomen, without any pelvic pathology, at shortly before or the onset of menstruation, which occur in up to 90% of woman [18]. Some days prior to menstruation, prostaglandins act on the uterine muscle where they increase the speed of onset of menstruation and smooth muscle contraction [19].

Premenstrual syndrome (PMS) is a set of physiological and affective symptoms happening within the one week prior to menses, after which there is an attenuation over a few days following the onset of menstrual bleeding, or shortly thereafter [20]. The frequency and intensity of PMS symptoms differ considerably between women [21, 22]. Between 70-90% of women experience one or more signs of physical discomfort or psychological symptoms during the luteal phase of their menstrual cycle [23, 24].

The presentation of IBS symptoms and the associated changes in bowel habit, may vary over the phases of the menstrual cycle, indicating a potential effect of gonadal hormones on gastrointestinal symptoms [23, 25]. We have previously reported that among 448 adolescent girls, the prevalence of IBS was significantly higher in the individuals with PD (19.9%), cases with PMS (13.6%), and individuals with both PMS and PD (17.4%) compared to health controls (8.1%) [26]. In spite of the documented co-occurrence of PD and PMS with IBS, these conditions have generally been explored as separate entities and so, there is scarce existing information on their combined impact. It remains unknown whether women with concurrent PMS and PD who report IBS have elevated levels of physiological and psychological distress. This study aimed to investigate that women who report IBS in addition to PD and PMS will also report more severe or frequent menstruation-associated symptoms and psychological complications compared to women with PD and PMS alone.

2.   Material and Methods

2.1.Study design and participants

This study was performed on female university students suffering from PMS and PD during November-December 2019 from 5 universities in Birjand city, Khorasan Province, Iran. The sample size was determined to achieve 80% power and α' = 0.05 according to a previous study [26] and it was determined that 173 cases would be needed for sufficient power. The

inclusion criteria of study were: a natural menstrual cycle, being single civil status (unmarried), having both PMS and PD which had started within 2 years of menarche. The exclusion criteria were any acute or chronic systemic diseases; and any history of pelvic or abdominal surgery. We also excluded girls with any endocrinopathy, endometriosis and/or adenomyosis, fibroids, secondary dysmenorrhea and other gynecological complications which were diagnosed by expert gynecologist or self-reported. Girls, who were using any medication and hormone therapy over the past year, were also elided. The study was approved by the Ethics Committee of Birjand University of Medical Sciences (BUMS) and informed consent was obtained from each participants.

2.2.Diagnosis of IBS, premenstrual syndrome and dysmenorrhea

2.2.1. Dysmenorrhea

These following criteria were used to define PD: pain beginning within 6-12 hours of menstruation, lower abdominal pain related with onset of menarche and extended over 8-72 hour, as well as low back pain or anterior thigh during menses [27].

The dysmenorrheal pain severity was measured in each participants using a visual analogue scale (VAS), with scores from 1-10. Pain was defined as "mild" when a female rated 1-3,"moderate" when rated 4-5, "severe" when rated 6-7, or "extreme severe" with a score of 8-10 [28].

2.2.2. Premenstrual syndrome
PMS was determined using the PSST (Premenstrual Syndrome Screening Tool) questionnaire [29], which consists of 19 items in three section (physical, behavioral and psychological symptoms) in the 5 days prior to menstruation of the previous 3 months. The severity of each symptom was graded from 0 to 3 based on 4-options Likert scale (0: none, 3: severe), covering the lowest and highest range of 0 and 57. The individuals who obtained scores

greater than 20 were enrolled to the present study. This scale was validated in Iran. Notably, the reliability, internal consistency, and the validity of the questionnaire for Iranian population were 0.9, 0.8, and 0.7, respectively[30].

2.2.3. Menstrual pattern

Menstrual patterns of participants were evaluated by standard questionnaires which included the menarcheal age, menstrual cycle length, duration and amount of flow[31].

2.2.4. IBS

This part of questionnaire consisted of questions about various gastrointestinal disorders, described on the basis of Rome III criteria translated into Persian. IBS was defined as repeated abdominal pain/discomfort at least 3 days per month in the last 2 months accompanied with $2\geq$ of the following criteria:1) Relief with defecation, 2) the beginning related with an alteration in frequency and 3) alteration in appearance of stool [1]. IBS and four subtypes including constipation-predominant (IBS-C), diarrhea predominant (IBS-D), mixed bowel habit (IBS-M), and unclassified IBS, were diagnosed based on the Rome III criteria and explanation of recent symptoms. The validity and reliability of this questionnaire in Iranian individuals has been reported previously [32].

2.3.Anthropometric measurements and blood collection

Demographic information was gathered by face-to-face interview. Anthropometric indices (waist and hip circumference, weight, height) and cardiac measurements were assessed using validated instruments and standard procedure in our health centers by expert paramedic. Body mass index (BMI) was also calculated by using this formula: weight (kg)/height (m2).

Five mL EDTA blood samples were collected from each participant in morning and hematological indices immediately were measured by using the SysmexK-800.

2.4.Neuropsychological assessment

Cognitive abilities were evaluated using the Cognitive Abilities Questionnaire (CAQ). The CAQ consists of 30 questions, each of which is scored on 1–5 and thus a total score obtaining from 30 to 150. Higher scores indicated superior cognition performances [33]. The CAQ measures memory, inhibitory control and selective attention, decision making, planning, sustained attention, social cognition and cognitive flexibility [34].

Depression Anxiety and Stress Scale (DASS-21) [35] is a commonly used, and has been well-validated for measuring of negative emotions. This 21-questions scale has 3 subscales (each contains 7 items) measuring depression, anxiety and stress, respectively. All items are scored on a zero to 3. Since DAS-21 is the short version of DAS-42; thus, the final score of each subclass must to be doubled. Higher score presenting more severe negative symptoms. The valid and reliable Persian revision of DASS-21 scale was used in this survey [36].

The Insomnia Severity Index (ISI) is a reliable tool which quantitatively measures a severity of insomnia [37]. The questionnaire involves 7 questions dealing on sleep disorder intensity, sleep-associated satisfaction and anxiety-associated sleeping disorder. Each items are rated from zero to 4 to provide a total score ranging 0- 28. Higher scores point out more degree of insomnia.

The Epworth Sleepiness Scale (ESS) is an accepted and validated questionnaire which can be used to measure daytime sleepiness. It have eight items with 4-point Likert scale (0-3) which quantifies the frequent probability of fall asleep in most common daily living conditions. Total scores range from 0-24 and higher scores indicate worsen sleepiness [38].

The Short Form health survey (SF-12) is a widely accepted tool for measuring health-related quality of life [39]. The generic instrument is a shorter version of the SF-36, and composed of 12 questions creates normalized physical and mental health subscales included in the SF-36. The Iranian version of the SF-12 revealed good psychometrically reliability and validity [40].

Personality Type A/B Inventory developed by Rathus has 25 items questionnaire and individuals concerning to their mood and states have to response: yes (score=1) or no (score=0) [41]. Type A personality describes a complex emotional individual who often have an aggressive mood, active, opponent, competitive, chivalrous and having different standards and activities. While, type B personality has features such as feeling less pressure, having regular rest/exercise, lower standard and slow working [42, 43]. This instrument divides individual personality types into two classes: type A (> score 13) and type B (≤13). The validity and reliability of this instrument was confirmed for Iranian population[41, 44].

2.5. Statistical analysis

Statistical analyses were conducted by using the SPSS for Windows version 16.0 (Statistical Package for Social Sciences Inc., Chicago, USA). Continuous variables are presented as mean ± SD and were compared between groups using independent sample T-test. Categorical variables presented as number (percent) and compare between groups by Chi-square test. The correlation between PSST score and neuropsychological tests was evaluated using Pearson correlation analysis. Univariate linear regression analysis was used to assess the effects of PSST scores on neuropsychological performances. A p value <0.05 was considered to be statistically significant.

3. Results

Of the 182 young females in the population sample, 31(17.0%) were found to have IBS. IBS subtypes included IBS-D 12.9%, IBS-C 9.7%, IBS-M 64.7%, and unsubtyped IBS 9.7%. The most predominant symptoms of IBS were alterations in bowel frequency (96.8%), alterations

in fecal consistency (90.3%), and abdominal pain which was alleviated by defecation (61.3%). Constipation was present in 41.9% of IBS subjects, diarrhea was found in 25.8%, and 22.6% presented with intermittent diarrhea and constipation. The clinical features of the participants are summarized in Table 1. No significant difference was found between IBS and Non-IBS groups in terms of age, BMI, SBP, DBP, waist: hip ratio and hematological indices (Table 1).

The distribution of menstrual pattern and common physiological symptoms of PMS between two groups are presented in Table 2. Average days of bleeding was significantly greater in the IBS group compared to non-IBS group (p=0.002). Also, in the non-IBS group, the mean pain severity of PSST scale was significantly lower than that in IBS groups (P=0.001). Among physiological symptoms of PMS, prevalence of muscular pain is statistically significant higher in group with IBS compared to No IBS group (p=0.049).

3.1.*Neuropsychological function in relation to IBS*

The women with IBS did not perform worse than the non-IBS group for all of the cognitive abilities tasks (P>0.05). But, the non-IBS individuals scored more favorably than the women with IBS in the Dass-21 test (depressed mood), insomnia intensity, severity of daytime sleepiness, and nocturnal sleeping (P<0.05; Table 3). Personality type of 48.4% of IBS cases were type A, whereas 36.4% of No-IBS group had type A personality, the difference was not statistically significant (P=0.16)

3.2.*Neuropsychological function in relation to PMS*

The correlation between the PSST score and cognitive abilities, depression, anxiety, stress, quality of life, insomnia and daytime sleepiness scores using Pearson correlation analysis are shown in Table 4. The PSST score was significantly correlated with scores for depression (r=0.29; p<0.001), anxiety (r=0.28; p<0.001), stress (r=0.32; p<0.001), insomnia (r=0.34;

p<0.001) and daytime sleepiness (r=0.31; p<0.001); while they were negatively correlated with cognitive abilities (r=-0.20; p=0.006) and quality of life(r=-0.42; p<0.001).

Univariate linear regression analysis was conducted to evaluate the association of PSST score and neuropsychological test scores in two IBS and No-IBS groups (Table 5). PSST score appeared to be a significant factor in determining the scores of depression, anxiety, stress, quality of life, insomnia and daytime sleepiness in both groups (P<0.05).

4. Discussion

To best of our knowledge, this work is the first study to show women who report IBS in addition to PD and PMS have a significantly higher PSST score, the average days of bleeding and frequency of some physical symptoms of PMS compared to those without it. They also more suffer from more degree of some neuropsychological problems including depression, insomnia, daytime sleepiness compared to IBS-cases. In contrast to the previous studies we have compared a group of affected patients (both PD and PMS) with women affected by both PD and PMS, and not with a healthy control group.

Identifying the co-occurrence of one or more physical or psychological complications is important. The reason is that this comorbidity can lead to difficulty in making a correct diagnosis because of the confounding manifestations of a patient's main problem; it can also affect the correct interpretation of research results, and causes worse health outcomes compared to the presence of a single problem.

Previous studies have indicated that PD and PMS co-occur in 25–50% of women with IBS [25, 45]. One the other hand, in one population-based, postal study, 26% of women with PD had IBS according to Rome III after 10 years follow-up [46]. In addition, female with IBS experience higher sensitivity to rectal distention than female without it, especially during menstruation [16], proposing elevated visceral sensitivity within the period of reducing

ovarian hormone amounts [47]. Regarding the somatic, psychological and gastrointestinal symptoms across the menstrual cycle, individuals with IBS had serious manifestations compared to healthy controls [25]. Altman and co-workers reported that the presence of PMS alone or PMS plus PD in IBS patients is associated with an exacerbation of symptoms reported during the luteal and the menses phases [48]. This suggests that the symptoms of IBS are aggravated during menses and cyclical alterations in rectal sensitivity is closely related to differently response to fluctuations in sex hormonal environment [16]. Therefore, it is crucial to account for concomitant other conditions that may influence symptom intensity and menstrual cycle phase in assessing treatment response. For example, the treatment of PMS woman with antidepressants which have anticholinergic features may further worsen symptoms in women with IBS-C.

Altogether, a total 16 tests of cognitive abilities, emotional/behavioral factors, sleep pattern and personality were administered to the study population. For four of these tests including depressed mood, insomnia, daytime sleepiness, and nocturnal sleep, the Non-IBS participants scored significantly more favorably compared to those with IBS. It has been shown that personality and affective characteristics are main elements of the IBS biopsychosocial model, being contributed in performance and dysregulation of the brain-gut connection, and involving to the formation, recurrence and relapse of IBS[49].

It has been reported that an increased level of neuroticism, conscientiousness, lie score, psychoticism, openness while decreased values of extraversion and crime in IBS-patients compared to healthy control [50, 51]. In a study among adolescents from Sri Lanka, IBS cases demonstrated higher hostility and aggression, negative self-esteem and self-adequacy, emotional unresponsiveness and instability as well as negative world view versus normal cases [52]. In Korean IBS patients, anxiety and depression trait that was evaluated using the Hospital Anxiety and Depression Scale (HADS) closely associated with the degree of IBS-

related symptoms [53]. In longitudinal study among Taiwanese population, IBS patients had 2.7- and 2.4-times greater risk of developing depression and sleep complication, respectively, than healthy controls [54], indicating IBS as a causal risk factor for psychiatric disorders.

Patients with IBS are more vulnerable to stressful experiences, which generate gastrointestinal manifestations [55]. Psychiatric complications are linked with variations in the formation of visceral sensations in IBS patients, which could explain the symptoms of IBS [56]. In accordance with our results, the prevalence of insomnia and sleepiness in patients with IBS was greater than healthy individuals in previous reports [57-59].

Insomnia is found in up to 20% of adults and is characterized by difficult falling asleep, maintenance of sleep, early morning awaking, poor sleep quality and lower satisfaction with sleep pattern [60]. A recent meta-analysis of published data claimed that sleep impairment were found in 37.6% of IBS was patients [61]. Interestingly, in a recent survey, the coexistence of both depression and insomnia is remarkably associated with higher risk of developing IBS in comparison with to each individual occurrence [62]. Balikji *et al* reported that IBS symptom severity was significantly correlated with insomnia, sleep quality, sleep onset latency as well as the frequency of night awakening [63].

The brain–gut connection contributed in the pathogenesis of IBS. Sleep disturbance cause to altering the activation of the autonomic nervous system implicating that sleep problems may be related with autonomic dysregulation [64, 65]. Moreover, IBS complaints, particularly pain, frequently have an adverse effect on sleep. One the other hand, sleep has a critical role in the immune system, and insufficient or sleep difficulty could induce immune dysfunction, which could lead in the inflammatory mucosal alterations observed in IBS cases [66, 67]. Thus, the relationship of IBS and insomnia is of a reciprocal nature. Deprivation or

insufficient sleep for any reason promotes pain. These evidences propose that the improvement of sleep will decrease IBS-related pain.

As we have found, results from several observational studies did not support the casual association between IBS disease process and cognitive impairments. IBS patients were not different from healthy controls regarding the executive function, absolute IQ and recognition scores, Spatial Working Memory tests, psychomotor speed, attention and interference tests, intelligence tests [68-70].

The question that arises is whether the severity of IBS aggravates the patients' anxiety depression and sleep problems or do their anxiety, depression and sleep problems exaggerate their IBS severity? Since this was a cross-sectional survey and not a longitudinal design, it is not possible to establish causal relationships. It is obvious that PMS symptoms and anxiety/depression or sleep problems have bidirectional and feedback impacts on each other.

Nevertheless, there are several limitations to this study. Due to its cross-sectional design of study, we were not able to determine cause and effect associations. The subjects with IBS in current work were not sub-grouped to those with IBS-C, IBS-D, or IBS-M because of the small sample size each subtype. Thus, further investigations are also needed to study IBS population in detail and described whether menstrual patterns and associated symptoms differ between IBS subtypes.

Conclusion:

IBS may be related to several psychiatric comorbidities, in particular depression, sleep problems and menstrual-associated disorders. In particular, IBS can exacerbate PMS symptoms. Another implication of the current study is the close relationship between cognitive dysfunction, depression, anxiety, sleep disturbance and PMS symptom severity. It

is most likely that the severity of gastrointestinal symptoms and psychological distress collectively cause the increased reporting of severe PMS symptoms in women. So, in PMS management, it is important to increase awareness among clinicians and gynecologists concerning to the relationships between PMS and IBS.

Author's contribution

A.B. performed all analyses and drafted the manuscript. A.B., S.K., M.A. and S.M. coordinated the fieldwork of the study. M.S., A.A., M.A., N.Z. and H.R. provided methodological feedback. A.B, Z.H., and G.F. supervised the overall research project and helped to draft the manuscript. All of the authors have read and confirmed the final manuscript. All authors state that they have no conflicts of interest.

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethics approval Ethical approval was obtained from the Birjand University of Medical Sciences and informed written consent was completed by all participants.

Informed consent Informed consent was obtained from all individual participants included in the study.

References:

1. Longstreth, G.F., et al., *Functional bowel disorders.* Gastroenterology, 2006. **130**(5): p. 1480-1491.
2. Canavan, C., J. West, and T. Card, *The epidemiology of irritable bowel syndrome.* Clinical epidemiology, 2014. **6**: p. 71.
3. Jahangiri, P., et al., *Irritable bowel syndrome in Iran: SEPAHAN systematic review No. 1.* International journal of preventive medicine, 2012. **3**(Suppl1): p. S1.
4. Vahedi, H., et al., *Irritable bowel syndrome: a review article.* Middle East journal of digestive diseases, 2010. **2**(2): p. 66.
5. Mayer, E.A., et al., *Brain imaging approaches to the study of functional GI disorders: a Rome working team report.* Neurogastroenterology & Motility, 2009. **21**(6): p. 579-596.
6. Elsenbruch, S., *Abdominal pain in Irritable Bowel Syndrome: a review of putative psychological, neural and neuro-immune mechanisms.* Brain, behavior, and immunity, 2011. **25**(3): p. 386-394.
7. Atkinson, W., et al., *Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial.* Gut, 2004. **53**(10): p. 1459-1464.
8. Barbara, G., et al., *The immune system in irritable bowel syndrome.* Journal of neurogastroenterology and motility, 2011. **17**(4): p. 349.
9. Camilleri, M., K. Lasch, and W. Zhou, *Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome.* American Journal of Physiology-Gastrointestinal and Liver Physiology, 2012.
10. Philpott, H., P. Gibson, and F. Thien, *Irritable bowel syndrome-An inflammatory disease involving mast cells.* Asia Pacific Allergy, 2011. **1**(1): p. 36-42.
11. Ringel, Y. and T. Ringel-Kulka, *The intestinal microbiota and irritable bowel syndrome.* Journal of clinical gastroenterology, 2015. **49**: p. S56-S59.
12. Walker, E.A., et al., *Comorbidity of gastrointestinal complaints, depression, and anxiety in the Epidemiologic Catchment Area (ECA) Study.* The American journal of medicine, 1992. **92**(1): p. S26-S30.
13. Drossman, D.A., *Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome?* The American journal of medicine, 1999. **107**(5): p. 41-50.
14. Elsaied, H.F., et al., *A study of sociodemographic factors and anxiety: depressive disorders among irritable bowel syndrome patients.* Egyptian Journal of Psychiatry, 2017. **38**(2): p. 97.
15. Tougas, G., *The autonomic nervous system in functional bowel disorders.* Gut, 2000. **47**(suppl 4): p. iv78-iv80.
16. Houghton, L., et al., *The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers.* Gut, 2002. **50**(4): p. 471-474.
17. McPherson, M.E. and L. Korfine, *Menstruation across time: menarche, menstrual attitudes, experiences, and behaviors.* Women's Health Issues, 2004. **14**(6): p. 193-200.
18. Iacovides, S., I. Avidon, and F.C. Baker, *What we know about primary dysmenorrhea today: a critical review.* Human reproduction update, 2015. **21**(6): p. 762-778.
19. Campbell, M.A. and P.J. McGrath, *Use of medication by adolescents for the management of menstrual discomfort.* Archives of pediatrics & adolescent medicine, 1997. **151**(9): p. 905-913.
20. Sternfeld, B., et al., *Severity of premenstrual symptoms in a health maintenance organization population.* Obstetrics & Gynecology, 2002. **99**(6): p. 1014-1024.
21. Yang, M., et al., *Burden of premenstrual dysphoric disorder on health-related quality of life.* Journal of women's health, 2008. **17**(1): p. 113-121.

22. Bahrami, A., et al., *High dose vitamin D supplementation can improve menstrual problems, dysmenorrhea, and premenstrual syndrome in adolescents.* Gynecological Endocrinology, 2018. **34**(8): p. 659-663.

23. Mishell, J.D., *Premenstrual disorders: epidemiology and disease burden.* The American journal of managed care, 2005. **11**(16 Suppl): p. S473-9.

24. Bahrami, A., et al., *Menstrual disorders and premenstrual symptoms in adolescents: prevalence and relationship to serum calcium and vitamin D concentrations.* Journal of Obstetrics and Gynaecology, 2018. **38**(7): p. 989-995.

25. Heitkemper, M.M., et al., *Symptoms across the menstrual cycle in women with irritable bowel syndrome.* The American journal of gastroenterology, 2003. **98**(2): p. 420-430.

26. Bahrami, A., et al., *The association of trace elements with premenstrual syndrome, dysmenorrhea and irritable bowel syndrome in adolescents.* European Journal of Obstetrics & Gynecology and Reproductive Biology, 2019. **233**: p. 114-119.

27. Awed, H., T. El-Saidy, and T. Amro, *The use of fresh Ginger herbs as a home remedy to relieve primary dysmenorrhea.* J Res Nurs Midwifery, 2013. **2**(8): p. 104-113.

28. Osayande, A.S. and S. Mehulic, *Diagnosis and initial management of dysmenorrhea.* American family physician, 2014. **89**(5): p. 341-346.

29. Steiner, M., M. Macdougall, and E. Brown, *The premenstrual symptoms screening tool (PSST) for clinicians.* Archives of Women's Mental Health, 2003. **6**(3): p. 203-209.

30. Siahbazi, S., et al., *Translation and psychometric properties of the Iranian version of the Premenstrual Symptoms Screening Tool (PSST).* Payesh (Health Monitor), 2011. **10**(4): p. 421-427.

31. Agarwal, A. and A. Venkat, *Questionnaire study on menstrual disorders in adolescent girls in Singapore.* Journal of pediatric and adolescent gynecology, 2009. **22**(6): p. 365-371.

32. Sorouri, M., et al., *Functional bowel disorders in Iranian population using Rome III criteria.* Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association, 2010. **16**(3): p. 154.

33. Nejati, V., *Cognitive abilities questionnaire: development and evaluation of psychometric properties.* Advances in Cognitive Science, 2013. **15**(2): p. 11-19.

34. Bahrami, A., et al., *The Association Between Neuropsychological Function with Serum Vitamins A, D, and E and hs-CRP Concentrations.* Journal of Molecular Neuroscience, 2019. **68**(2): p. 243-250.

35. Henry, J.D. and J.R. Crawford, *The short‐form version of the Depression Anxiety Stress Scales (DASS‐21): Construct validity and normative data in a large non‐clinical sample.* British journal of clinical psychology, 2005. **44**(2): p. 227-239.

36. Sahebi, A., M.J. Asghari, and R. Salari, *Validation of depression anxiety and stress scale (DASS-21) for an Iranian population.* 2005.

37. Yazdi, Z., et al., *Validity and reliability of the Iranian version of the insomnia severity index.* The Malaysian journal of medical sciences: MJMS, 2012. **19**(4): p. 31.

38. Haghighi, K.S., et al., *The Epworth Sleepiness Scale: translation and validation study of the Iranian version.* Sleep and Breathing, 2013. **17**(1): p. 419-426.

39. Ware, J.E., et al., *SF-12v2™: How to score version 2 of the SF-12® health survey.* 2002.

40. Montazeri, A., et al., *The Iranian version of 12-item Short Form Health Survey (SF-12): factor structure, internal consistency and construct validity.* BMC public health, 2009. **9**(1): p. 341.

41. Mousaviraja, A., et al., *Personality type and drug abuse among Iranian young adults: A comparative study.* Life Sci J, 2014. **11**(4s): p. 251-6.

42. Friedman, M., *Type A behavior: Its diagnosis and treatment*. 1996: Springer Science & Business Media.

43. Friedman, M., *Rosenman. RH: Type A Behavior and Your Heart.* A. Knopf, New York, 1974.

44. Sanjoori, H. and P. Asgari, *A Comparative Analysis of Self-Actualization, Risk Taking, Accountability and Happiness among Students with A/B Personality Types in Islamic Azad*

University of Ahvaz. International Journal of Humanities and Cultural Studies (IJHCS) ISSN 2356-5926, 2016: p. 757-768.

45.   Whitehead, W.E., O. Palsson, and K.R. Jones, *Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications?* Gastroenterology, 2002. **122**(4): p. 1140-1156.

46.   Olafsdottir, L.B., et al., *Natural history of irritable bowel syndrome in women and dysmenorrhea: a 10-year follow-up study.* Gastroenterology research and practice, 2012. **2012**.

47.   Jackson, N., et al., *Does the menstrual cycle affect anorectal physiology?* Digestive diseases and sciences, 1994. **39**(12): p. 2607-2611.

48.   Altman, G., et al., *Increased symptoms in female IBS patients with dysmenorrhea and PMS.* Gastroenterology Nursing, 2006. **29**(1): p. 4-11.

49.   Muscatello, M.R.A., et al., *Personality traits and emotional patterns in irritable bowel syndrome.* World journal of gastroenterology, 2016. **22**(28): p. 6402.

50.   Elaziz, H.M.A., et al., *Psychosocial aspects and personality dimensions among a sample of patients with irritable bowel syndrome.* Egyptian Journal of Psychiatry, 2019. **40**(3): p. 147.

51.   Farnam, A., et al., *Personality factors and profiles in variants of irritable bowel syndrome.* World Journal of Gastroenterology: WJG, 2007. **13**(47): p. 6414.

52.   Ranasinghe, N., et al., *Functional gastrointestinal diseases and psychological maladjustment, personality traits and quality of life.* BMC gastroenterology, 2018. **18**(1): p. 33.

53.   Cho, H.S., et al., *Anxiety, depression and quality of life in patients with irritable bowel syndrome.* Gut and liver, 2011. **5**(1): p. 29.

54.   Lee, Y.-T., et al., *Risk of psychiatric disorders following irritable bowel syndrome: a nationwide population-based cohort study.* PLoS One, 2015. **10**(7).

55.   Drossman, D.A., et al., *AGA technical review on irritable bowel syndrome.* Gastroenterology, 2002. **123**(6): p. 2108-2131.

56.   Guthrie, E., et al., *Changes in tolerance to rectal distension correlate with changes in psychological state in patients with severe irritable bowel syndrome.* Psychosomatic Medicine, 2004. **66**(4): p. 578-582.

57.   Abdulahad, S., et al., *Irritable bowel syndrome, immune fitness, and insomnia: Results from an online survey among people reporting sleep complaints.* Sleep and Vigilance, 2019. **3**(2): p. 121-129.

58.   Jarrett, M., et al., *Sleep disturbance influences gastrointestinal symptoms in women with irritable bowel syndrome.* Digestive diseases and sciences, 2000. **45**(5): p. 952-959.

59.   Kim, S.Y., et al., *Self-reported sleep impairment in functional dyspepsia and irritable bowel syndrome.* Journal of neurogastroenterology and motility, 2018. **24**(2): p. 280.

60.   Edinger, J.D., et al., *Insomnia and the eye of the beholder: Are there clinical markers of objective sleep disturbances among adults with and without insomnia complaints?* Journal of Consulting and Clinical Psychology, 2000. **68**(4): p. 586-593.

61.   Wang, B., R. Duan, and L. Duan, *Prevalence of sleep disorder in irritable bowel syndrome: A systematic review with meta-analysis.* Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association, 2018. **24**(3): p. 141.

62.   Lee, S.K., et al., *The association between irritable bowel syndrome and the coexistence of depression and insomnia.* Journal of psychosomatic research, 2017. **93**: p. 1-5.

63.   Balikji, S., et al., *The association of insomnia, perceived immune functioning, and irritable bowel syndrome complaints.* Journal of clinical medicine, 2018. **7**(9): p. 238.

64.   Miglis, M.G., *Autonomic dysfunction in primary sleep disorders.* Sleep medicine, 2016. **19**: p. 40-49.

65.   Tobaldini, E., et al., *Sleep, sleep deprivation, autonomic nervous system and cardiovascular diseases.* Neuroscience & Biobehavioral Reviews, 2017. **74**: p. 321-329.

66.   Everson, C.A. and L.A. Toth, *Systemic bacterial invasion induced by sleep deprivation.* American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2000. **278**(4): p. R905-R916.

67.   Bøyum, A., et al., *The effect of strenuous exercise, calorie deficiency and sleep deprivation on white blood cells, plasma immunoglobulins and cytokines.* Scandinavian journal of immunology, 1996. **43**(2): p. 228-235.

68.   Berrill, J., et al., *An observational study of cognitive function in patients with irritable bowel syndrome and inflammatory bowel disease.* Neurogastroenterology & Motility, 2013. **25**(11): p. 918-e704.

69.   Kennedy, P., et al., *Cognitive performance in irritable bowel syndrome: evidence of a stress-related impairment in visuospatial memory.* Psychological medicine, 2014. **44**(7): p. 1553-1566.

70.   Attree, E.A., et al., *Cognitive function in people with chronic illness: inflammatory bowel disease and irritable bowel syndrome.* Applied neuropsychology, 2003. **10**(2): p. 96-104.

Table 1. Demographic, anthropometrics and hematological characteristics of IBS and No-IBS women

Variable	No-IBS (n=151)	IBS (n=31)	P value *
Age (years)	20.7±1.7	20.4±4.0	0.48
BMI (kg/m^2)	20.9±2.9	20.3±2.8	0.32
SBP(mmHg)	10.6±0.96	10.8±0.99	0.44
DBP(mmHg)	7.1±0.75	7.4±0.77	0.56
WHR	0.73±0.04	0.74±0.03	0.46
Hematological indices			
WBC (10^9 cells/L)	6.8±1.8	7.1±1.9	0.46
RBC(10^{12} cells/L)	4.8±0.5	4.8±0.4	0.89
HCT (%)	41.6±3.6	41.1±3.3	0.46
Hb (g/dL)	13.9±1.4	13.8±1.6	0.67

BMI: body mass index; Hb: hemoglobin; HCT: hematocrit; IBS: irritable bowel syndrome; SBP: systolic blood pressure; DBP: diastolic blood pressure; WHR: waist: hip ratio.

Data presented as mean±SD

*By using independent sample T test

Table 2. Relationship between menstrual pattern, PSST score and physiological symptoms with presence of IBS

Variable	No-IBS (n=151)	IBS (n=31)	P value *
Age of menstruation, years	13.1±1.4	13.1±1.2	0.77
Average days of bleeding	6.5±1.1	7.8±4.1	**0.002**
Duration of the menstruation cycle (day)	28.0±3.9	27.4±5.4	0.52
PSST sore	32.2±9.8	38.7±9.7	**0.001**
Dysmenorrhea pain score	7.2±2.1	7.3±2.6	0.92
Menstruation-associated physical symptoms, n(%)			
Tender breasts	94(62.3)	22(71)	0.36
Backache	142(94.0)	31(100)	0.16
feeling of bloating	142(94.0)	30(96.8)	0.54
Weight gain	69(45.7)	17(54.8)	0.35
Swelling of the limbs	78(51.7)	22(71.0)	**0.049**
joint or muscle pain	129(85.4)	30(96.8)	0.83
Gastrointestinal symptoms	122(80.8)	27(87.1)	0.40
Use of medicine for relieving pain	82(54.3)	15(48.4)	0.66
Data presented as mean±SD or number (%). *By using independent sample T test or chi-square test as appropriate.			

Table 3. Association of cognitive ability, emotional performance, personality and sleep pattern with presence of IBS.

Variable (score)	No-IBS (n=151)	IBS (n=31)	P value[*]
Test of cognitive abilities			
Memory	25.6±3.1	24.5±4.5	0.08
Inhibitory control and selective attention	22.0±3.8	21.4±4.6	0.45
Decision making	19.0±3.7	18.2±3.7	0.28
Planning	11.1±2.8	10.5±3.0	0.26
Sustain attention	9.6±2.4	8.7±2.4	0.06
Social cognition	10.6±2.1	11.2±2.0	0.16
Cognitive flexibility	14.6±2.8	14.1±2.8	0.35
Total cognitive ability task	112.6±14.0	108.6±14.8	0.15
Dass-21			
Depression	10.5±8.6	14.0±10.2	**0.046**
Anxiety	8.5±6.0	10.7±7.4	0.078
Stress	17.0±9.6	19.3±11.4	0.26
Quality of life (SF-12)			
Physical health	15.9±2.4	15.3±3.0	0.25
Mental health	16.5±3.6	15.7±4.2	0.24
Total Quality of life score	32.4±5.0	31.5±5.7	0.36
Test of sleep pattern			
Insomnia score (ISI)	5.7±6.4	8.7±8.3	**0.025**
Daytime sleepiness score (ESS)	5.8±5.7	8.9±6.2	**0.008**
Nocturnal sleep hours	7.4±1.3	6.7±1.5	**0.008**
Personality			
Type A	55(36.4)	15(48.4)	0.16
Type B	96(63.6)	16(51.6)	

Data presented as mean±SD or number (%).

*Obtained from independent sample T-test or chi-square tests as appropriate.

Table 4. Correlation matrix between PSST score and neuropsychological tests in subjects with PMS and PD

Variables		PSST score	Cognitive abilities	Depression	Anxiety	Stress	Quality of life	Insomnia
Cognitive abilities	r	-0.20						
	p	**0.006**	Cognitive abilities					
Depression	r	0.29	-0.50					
	p	**<0.001**	**<0.001**	Depression				
Anxiety	r	0.28	-0.46	0.57				
	p	**<0.001**	**<0.001**	**<0.001**	Anxiety			
Stress	r	0.32	-0.52	0.57	0.61			
	p	**<0.001**	**<0.001**	**<0.001**	**<0.001**	Stress		
Quality of life	r	-0.42	0.36	-0.48	-0.44	-0.51		
	p	**<0.001**	**<0.001**	**<0.001**	**<0.001**	**<0.001**	Quality of life	
Insomnia	r	0.34	-0.12	0.22	0.33	0.24	-0.41	
	p	**<0.001**	0.11	**0.003**	**<0.001**	**0.001**	**<0.001**	Insomnia
Daytime sleepiness	r	0.31	-0.32	0.30	0.37	0.23	-0.32	0.52
	p	**<0.001**	**<0.001**	**<0.001**	**<0.001**	0.002	**<0.001**	**<0.001**

Table 5. Linear regression analysis the effect of PSST score on cognitive abilities, depression, anxiety, stress, quality of life, insomnia and daytime sleepiness scores as the dependent variables across IBS categories.

Variables	No-IBS		IBS	
	B	P value	B	P value
Cognitive abilities	-0.21	0.07	-0.53	0.05
Depression	0.20	**0.004**	0.41	**0.032**
Anxiety	0.12	**0.014**	0.36	**0.008**
Stress	0.25	**0.002**	0.62	**0.002**
Quality of life	-0.18	**<0.001**	-0.44	**<0.001**
Insomnia	0.16	**0.002**	0.50	**0.001**
Daytime sleepiness	0.14	**0.003**	0.29	**0.010**